1+ week, 2+ day ago  (284+ words) Real-world INFUSE results show IV eptinezumab boosts good days and cuts monthly headache days for hard-to-treat migraine patients. New data from the real-world INFUSE trial showed that switching to intravenous eptinezumab (Vyepti; Lundbeck) was associated with meaningful real-world improvements in…...

3+ week, 5+ day ago  (324+ words) An interim DSMB review halted the rivaroxaban arm of the NIH-funded CAPTIVA trial in symptomatic intracranial atherosclerotic stroke due to increased safety events and futility compared with standard dual antiplatelet therapy. CAPTIVA is a 2-stage, double-blind, randomized trial enrolling adults…...

3+ week, 6+ day ago  (223+ words) In honor of Duchenne Muscular Dystrophy Awareness Week, observed February 13 to 19, we're taking a look at the pipeline of therapeutic candidates in development for DMD. In honor of DMD Awareness Week, observed annually from February 13 to 19 by the patient and clinician…...

5+ mon, 3+ week ago  (605+ words) Avidity's del-zota shows promising results in reversing disease progression in Duchenne muscular dystrophy, paving the way for potential FDA approval. Newly announced data from the EXPLORE44 (NCT05670730) and EXPLORE44-open label extension (OLE) trials showed that treatment with Avidity's del-zota led…...

3+ week, 6+ day ago  (674+ words) NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats. Treatment with obexelimab (Zenas BioPharma), a novel bifunctional monoclonal antibody targeting CD19 and Fc" receptor IIb (Fc"RIIb), led to a near-complete suppression…...

1+ mon, 12+ hour ago  (203+ words) In the phase 3 PERSEUS trial, Bruton tyrosine kinase inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis. New late-breaking data from the phase 3 PERSEUS trial (NCT04458051) showed that tolebrutinib (Sanofi), an investigational…...

1+ mon, 15+ hour ago  (118+ words) In this video, Micah Luftig provided an overview of the growing body of evidence linking Epstein-Barr virus (EBV) to the development of multiple sclerosis, highlighting decades of research suggesting that immune responses to EBV may trigger autoimmune mechanisms through molecular…...

1+ mon, 1+ day ago  (124+ words) Unearthing Whether MS Onset Occurs Before EBV Infection'NeurologyLive Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights AGNOS Study Results Demonstrate Ofatumumab's Impact on Neurofilament Light, GFAP Inside the Push for Myelin Repair: Riley Bove, MD Rethinking Multiple Sclerosis…...

1+ mon, 1+ day ago  (299+ words) A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women's health. To that end, I do hope that the BTK inhibitors end up coming to market....

1+ mon, 2+ day ago  (207+ words) Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile. "From a safety and tolerability standpoint, we we're very encouraged," senior study author told…...